

# Erratum

The authors of the Clinical report 'Pathological complete response rates comparing 3 versus 6 cycles of epirubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer' [1] wish to bring to the readers attention, the error in the report as follows: two patients included in the report were not randomly assigned to group 2, but received 6 cycles of chemotherapy without randomization. The statistical calculations for the study as published are correct but will have to be reconsidered after exclusion of these two patients.

## Reference

1. Reitsamer R, Peintinger F, Prokop E, Hitzl W. Pathological complete response rates comparing 3 versus 6 cycles of epirubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. *Anticancer Drugs* (2005); **16**:867–870.